DRG 380 Overview

DRG 380 covers hospital admissions for complicated peptic ulcer disease with a Major Complication or Comorbidity present, typically involving bleeding, perforation, obstruction, or other significant complications that require inpatient medical or surgical management. This Diagnosis-Related Group is clinically significant because the presence of a Major Complication or Comorbidity increases resource use, length of stay, and intensity of care compared with uncomplicated peptic ulcer admissions. For Medicare payment, classifying a case to DRG 380 affects relative payment weight and reimbursement under the inpatient prospective payment system administered by the Centers for Medicare & Medicaid Services. Accurate coding of principal diagnosis and accompanying Major Complication or Comorbidity is essential for determining the appropriate Diagnosis-Related Group assignment and associated payment.

• Acute endoscopic and procedural intervention trials: studies evaluating timing, technique, and safety of urgent endoscopic hemostasis or minimally invasive surgical approaches in hospitalized patients with bleeding or perforated complicated peptic ulcers. These trials focus on adult inpatients presenting with active hemorrhage, perforation, or sepsis who require immediate procedural care, comparing earlier versus delayed endoscopy, different hemostatic modalities, or adjunctive intensive-care strategies. Results inform best practices for acute management that impact length of stay, complication rates, and short‑term resource utilization—key concerns for clinicians, hospitals, and payers handling DRG 380 cases.
• Comparative effectiveness studies of inpatient medical management strategies: randomized or pragmatic trials comparing regimen components such as high‑dose acid suppression strategies, stress ulcer prophylaxis algorithms, transfusion thresholds, and antimicrobial approaches in patients with complicated peptic ulcers and major comorbidities. These studies enroll medically complex hospitalized patients (often elderly with cardiopulmonary or renal comorbidities) to determine which nonprocedural inpatient therapies reduce rebleeding, organ dysfunction, and need for reintervention. Findings help providers optimize care pathways and help payers predict resource needs and potential cost offsets from reduced complications or readmissions.
• Post‑discharge outcomes and transitional care trials: studies testing discharge planning, medication adherence interventions, H. pylori eradication confirmation pathways, and close outpatient follow‑up models in survivors of complicated peptic ulcer admission to reduce readmissions, recurrent bleeding, and long‑term morbidity. These trials target patients discharged after treatment for bleeding or perforation, often with complex regimens and comorbid conditions, and evaluate outcomes at 30, 90, and 180 days including readmission rates and outpatient resource use. Evidence from these trials is relevant to clinicians and payers because improved transitional care can lower avoidable readmissions and downstream costs while improving patient safety and long‑term outcomes.